Business

What does Alnylam mean?

By: Aaron LivniUpdated: February 25, 2021

Categories

Site Statistics

  • Questions
    94,481
  • Answers
    1,984,101
  • Categories
    21
  • Last Updated
    May 21, 2022
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Similarly, you may ask, when was Alnylam founded?

June 2002

Also to know, who makes Patisiran?

It is the first small interfering RNA-based drug approved by the FDA and the first drug approved by the FDA to treat this condition. It is a gene silencing drug that interferes with the production of an abnormal form of transthyretin. Patisiran was developed and is marketed by Alnylam.

How many employees does Alnylam have?

1,400 full

How do you name a biotech company?

Essential Rules for Developing Biotech Company Name Ideas
  1. Get creative.
  2. Stay focused.
  3. Think of ideas.
  4. Know the naming requirements.
  5. Plan ahead.
  6. Validate the name.
  7. Take your time.
  8. Biotech Company Domains for Sale.

Related

What is RNAi Therapeutics?

RNAi therapeutic, such as siRNA or microRNA (miRNA), are a new class of drug molecules that can be used to treat disease by attacking messenger RNA (mRNA) of the targeted genes in cells (Bumcrot et al., 2006) (Fig.

What is Onpattro?

Onpattro is used to treat polyneuropathy (damage of multiple nerves throughout the body) in adults with hATTR. Onpattro can help reduce symptoms such as pain, numbness, tingling, abnormal heartbeats, diarrhea, constipation, weakness, and problems with movement in your arms or legs.

How much does Onpattro cost?

Onpattro will have an list price of $450,000 per patient per year for the average patient. (The drug is dosed based on weight.)

What is Onpattro used for?

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

What is transthyretin amyloidosis?

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Other areas of amyloidosis include the heart, kidneys, eyes, and gastrointestinal tract.

What is Hereditary transthyretin amyloidosis?

Familial transthyretin amyloidosis (FTA) is a rare inherited condition characterized by abnormal build-up of a protein called amyloid in the body's organs and tissues . Symptoms start in adulthood and get worse over time. Inheritance is autosomal dominant , but not all people with a TTR gene mutation will develop FTA.